• Profile
Close

Multicentre study of short‐course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer

British Journal of Surgery Apr 03, 2020

Kok END, Havenga K, Tanis PJ, et al. - Researchers examined if short‐course pelvic radiotherapy (5 × 5 Gy) followed by systemic therapy and local treatment is feasible and effective for managing all tumor sites in patients with potentially curable stage IV rectal cancer in daily practice. In this retrospective study, 169 patients were included from eight tertiary referral centers in the Netherlands; the median follow‐up period was 49·5 months. The entire treatment schedule was completed by 65·7%. Three‐year progression‐free survival rate was 24·2% and overall survival (OS) rate was 48·8%, respectively. Patients who responded well and completed the treatment schedule had median OS of 51·5 months vs 15·1 months for patients who did not complete the treatment. In 87·0% of all patients, the primary tumor symptoms were adequately controlled. Findings suggest that symptoms in most patients could be relieved with multimodal treatment, and good survival rates among those who were able to complete the schedule.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay